Sutro Biopharma (FRA:S09) Long-Term Capital Lease Obligation : €19.7 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Long-Term Capital Lease Obligation?

Sutro Biopharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €19.7 Mil.

Sutro Biopharma's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€23.3 Mil) to Dec. 2023 (€21.2 Mil) and declined from Dec. 2023 (€21.2 Mil) to Mar. 2024 (€19.7 Mil).

Sutro Biopharma's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€27.6 Mil) to Dec. 2022 (€27.9 Mil) but then declined from Dec. 2022 (€27.9 Mil) to Dec. 2023 (€21.2 Mil).

Sutro Biopharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sutro Biopharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Long-Term Capital Lease Obligation Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

27.63

27.92

21.23

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															26.22	24.48	23.30	21.23	19.69

Sutro Biopharma (FRA:S09) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sutro Biopharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (FRA:S09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines